nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—CYP3A5—Irinotecan—colon cancer	0.107	0.301	CbGbCtD
Flutamide—CYP3A5—Vincristine—colon cancer	0.0939	0.263	CbGbCtD
Flutamide—CYP1A2—Fluorouracil—colon cancer	0.0767	0.215	CbGbCtD
Flutamide—AR—scrotum—colon cancer	0.049	0.301	CbGeAlD
Flutamide—CYP3A4—Irinotecan—colon cancer	0.0419	0.117	CbGbCtD
Flutamide—CYP3A4—Vincristine—colon cancer	0.0366	0.103	CbGbCtD
Flutamide—Proctitis—Fluorouracil—colon cancer	0.0134	0.0558	CcSEcCtD
Flutamide—Urine color abnormal—Capecitabine—colon cancer	0.00967	0.0404	CcSEcCtD
Flutamide—AHR—smooth muscle tissue—colon cancer	0.00759	0.0466	CbGeAlD
Flutamide—Necrolysis epidermal—Methotrexate—colon cancer	0.00748	0.0312	CcSEcCtD
Flutamide—Chromaturia—Capecitabine—colon cancer	0.00638	0.0266	CcSEcCtD
Flutamide—AHR—digestive system—colon cancer	0.00599	0.0368	CbGeAlD
Flutamide—Nodule—Methotrexate—colon cancer	0.00577	0.0241	CcSEcCtD
Flutamide—AHR—bone marrow—colon cancer	0.00552	0.0339	CbGeAlD
Flutamide—AHR—vagina—colon cancer	0.00529	0.0325	CbGeAlD
Flutamide—AHR—liver—colon cancer	0.00446	0.0274	CbGeAlD
Flutamide—Neoplasm malignant—Irinotecan—colon cancer	0.00399	0.0166	CcSEcCtD
Flutamide—CYP1B1—smooth muscle tissue—colon cancer	0.00395	0.0243	CbGeAlD
Flutamide—AR—epithelium—colon cancer	0.00388	0.0239	CbGeAlD
Flutamide—CYP1B1—renal system—colon cancer	0.0038	0.0234	CbGeAlD
Flutamide—AR—smooth muscle tissue—colon cancer	0.00374	0.023	CbGeAlD
Flutamide—Loss of libido—Methotrexate—colon cancer	0.00368	0.0153	CcSEcCtD
Flutamide—AR—renal system—colon cancer	0.0036	0.0221	CbGeAlD
Flutamide—Ulcer—Irinotecan—colon cancer	0.0036	0.015	CcSEcCtD
Flutamide—Ulcer—Fluorouracil—colon cancer	0.00345	0.0144	CcSEcCtD
Flutamide—AHR—lymph node—colon cancer	0.00342	0.021	CbGeAlD
Flutamide—Pulmonary embolism—Irinotecan—colon cancer	0.00341	0.0142	CcSEcCtD
Flutamide—CYP1B1—lymphoid tissue—colon cancer	0.00316	0.0194	CbGeAlD
Flutamide—CYP1B1—digestive system—colon cancer	0.00312	0.0192	CbGeAlD
Flutamide—Neoplasm—Irinotecan—colon cancer	0.00308	0.0129	CcSEcCtD
Flutamide—Herpes zoster—Capecitabine—colon cancer	0.00303	0.0126	CcSEcCtD
Flutamide—AR—lymphoid tissue—colon cancer	0.00299	0.0184	CbGeAlD
Flutamide—AR—digestive system—colon cancer	0.00295	0.0182	CbGeAlD
Flutamide—CYP1A1—epithelium—colon cancer	0.0029	0.0178	CbGeAlD
Flutamide—CYP2C19—digestive system—colon cancer	0.00274	0.0168	CbGeAlD
Flutamide—CYP1A2—renal system—colon cancer	0.00273	0.0168	CbGeAlD
Flutamide—CYP1A1—renal system—colon cancer	0.00269	0.0165	CbGeAlD
Flutamide—CYP3A5—renal system—colon cancer	0.00263	0.0162	CbGeAlD
Flutamide—AR—vagina—colon cancer	0.00261	0.016	CbGeAlD
Flutamide—Rectal haemorrhage—Capecitabine—colon cancer	0.00252	0.0105	CcSEcCtD
Flutamide—Dermatitis bullous—Fluorouracil—colon cancer	0.00248	0.0103	CcSEcCtD
Flutamide—CYP2C19—vagina—colon cancer	0.00242	0.0149	CbGeAlD
Flutamide—Ulcer—Capecitabine—colon cancer	0.00241	0.0101	CcSEcCtD
Flutamide—Interstitial lung disease—Methotrexate—colon cancer	0.0024	0.01	CcSEcCtD
Flutamide—CYP1B1—liver—colon cancer	0.00232	0.0143	CbGeAlD
Flutamide—Aspartate aminotransferase increased—Vincristine—colon cancer	0.00229	0.00954	CcSEcCtD
Flutamide—Pulmonary embolism—Capecitabine—colon cancer	0.00228	0.00951	CcSEcCtD
Flutamide—Herpes zoster—Methotrexate—colon cancer	0.00225	0.0094	CcSEcCtD
Flutamide—CYP1A2—digestive system—colon cancer	0.00224	0.0137	CbGeAlD
Flutamide—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.00223	0.00929	CcSEcCtD
Flutamide—CYP1A1—digestive system—colon cancer	0.00221	0.0136	CbGeAlD
Flutamide—AR—liver—colon cancer	0.0022	0.0135	CbGeAlD
Flutamide—CYP3A5—digestive system—colon cancer	0.00216	0.0133	CbGeAlD
Flutamide—Neoplasm—Capecitabine—colon cancer	0.00206	0.0086	CcSEcCtD
Flutamide—Ecchymosis—Capecitabine—colon cancer	0.00206	0.0086	CcSEcCtD
Flutamide—CYP2C19—liver—colon cancer	0.00204	0.0125	CbGeAlD
Flutamide—Erectile dysfunction—Vincristine—colon cancer	0.00202	0.00843	CcSEcCtD
Flutamide—Photosensitivity reaction—Vincristine—colon cancer	0.002	0.00836	CcSEcCtD
Flutamide—CYP3A4—renal system—colon cancer	0.00197	0.0121	CbGeAlD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—HNF4A—colon cancer	0.00195	0.00807	CbGpPWpGaD
Flutamide—CYP1A1—vagina—colon cancer	0.00195	0.012	CbGeAlD
Flutamide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00195	0.00806	CbGpPWpGaD
Flutamide—CYP3A5—Irinotecan Pathway—APC—colon cancer	0.00193	0.00799	CbGpPWpGaD
Flutamide—CYP3A5—vagina—colon cancer	0.0019	0.0117	CbGeAlD
Flutamide—Diabetes mellitus—Capecitabine—colon cancer	0.0019	0.00794	CcSEcCtD
Flutamide—Photosensitivity reaction—Fluorouracil—colon cancer	0.00187	0.0078	CcSEcCtD
Flutamide—Jaundice—Irinotecan—colon cancer	0.00186	0.00775	CcSEcCtD
Flutamide—Haemolytic anaemia—Capecitabine—colon cancer	0.00183	0.00765	CcSEcCtD
Flutamide—Ulcer—Methotrexate—colon cancer	0.00179	0.00749	CcSEcCtD
Flutamide—Libido decreased—Capecitabine—colon cancer	0.00178	0.00745	CcSEcCtD
Flutamide—CYP1B1—lymph node—colon cancer	0.00178	0.011	CbGeAlD
Flutamide—Hot flush—Capecitabine—colon cancer	0.00177	0.00738	CcSEcCtD
Flutamide—Increased appetite—Capecitabine—colon cancer	0.00176	0.00735	CcSEcCtD
Flutamide—CYP1A2—Metapathway biotransformation—CHST4—colon cancer	0.00176	0.00729	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.00176	0.00729	CbGpPWpGaD
Flutamide—Menopausal symptoms—Capecitabine—colon cancer	0.00175	0.00732	CcSEcCtD
Flutamide—Dermatitis bullous—Capecitabine—colon cancer	0.00173	0.00723	CcSEcCtD
Flutamide—AHR—Adipogenesis—PPARG—colon cancer	0.00171	0.00709	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.00171	0.00707	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—TYMS—colon cancer	0.0017	0.00706	CbGpPWpGaD
Flutamide—Pulmonary embolism—Methotrexate—colon cancer	0.0017	0.00708	CcSEcCtD
Flutamide—AR—lymph node—colon cancer	0.00169	0.0104	CbGeAlD
Flutamide—CYP1A2—liver—colon cancer	0.00167	0.0102	CbGeAlD
Flutamide—Cystitis noninfective—Methotrexate—colon cancer	0.00166	0.00692	CcSEcCtD
Flutamide—CYP1A1—liver—colon cancer	0.00164	0.0101	CbGeAlD
Flutamide—Disturbance in sexual arousal—Capecitabine—colon cancer	0.00164	0.00685	CcSEcCtD
Flutamide—Cystitis—Methotrexate—colon cancer	0.00164	0.00684	CcSEcCtD
Flutamide—CYP3A4—digestive system—colon cancer	0.00162	0.00995	CbGeAlD
Flutamide—CYP3A5—liver—colon cancer	0.00161	0.00988	CbGeAlD
Flutamide—AR—Nuclear Receptors—PPARG—colon cancer	0.00155	0.00642	CbGpPWpGaD
Flutamide—Bladder pain—Methotrexate—colon cancer	0.00153	0.0064	CcSEcCtD
Flutamide—Ecchymosis—Methotrexate—colon cancer	0.00153	0.0064	CcSEcCtD
Flutamide—Neoplasm—Methotrexate—colon cancer	0.00153	0.0064	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—MSH6—colon cancer	0.00152	0.00631	CbGpPWpGaD
Flutamide—Gynaecomastia—Methotrexate—colon cancer	0.00152	0.00634	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.0015	0.00621	CbGpPWpGaD
Flutamide—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.00149	0.00622	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.00149	0.00622	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.00148	0.00613	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.00145	0.006	CbGpPWpGaD
Flutamide—Erythema—Fluorouracil—colon cancer	0.00143	0.00595	CcSEcCtD
Flutamide—Diabetes mellitus—Methotrexate—colon cancer	0.00142	0.00591	CcSEcCtD
Flutamide—Anaemia—Vincristine—colon cancer	0.00141	0.0059	CcSEcCtD
Flutamide—Ill-defined disorder—Irinotecan—colon cancer	0.00138	0.00577	CcSEcCtD
Flutamide—CYP3A5—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00138	0.00572	CbGpPWpGaD
Flutamide—Anaemia—Irinotecan—colon cancer	0.00138	0.00574	CcSEcCtD
Flutamide—Leukopenia—Vincristine—colon cancer	0.00137	0.00571	CcSEcCtD
Flutamide—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.00136	0.00563	CbGpPWpGaD
Flutamide—Malaise—Irinotecan—colon cancer	0.00134	0.0056	CcSEcCtD
Flutamide—CYP3A5—Metapathway biotransformation—CHST5—colon cancer	0.00134	0.00556	CbGpPWpGaD
Flutamide—Leukopenia—Irinotecan—colon cancer	0.00133	0.00556	CcSEcCtD
Flutamide—Hypertension—Vincristine—colon cancer	0.00132	0.00551	CcSEcCtD
Flutamide—Anaemia—Fluorouracil—colon cancer	0.00132	0.0055	CcSEcCtD
Flutamide—Photosensitivity reaction—Capecitabine—colon cancer	0.00131	0.00545	CcSEcCtD
Flutamide—Hyperglycaemia—Capecitabine—colon cancer	0.00129	0.00538	CcSEcCtD
Flutamide—Hypertension—Irinotecan—colon cancer	0.00129	0.00536	CcSEcCtD
Flutamide—Leukopenia—Fluorouracil—colon cancer	0.00128	0.00533	CcSEcCtD
Flutamide—CYP1A1—Metapathway biotransformation—CHST5—colon cancer	0.00127	0.00525	CbGpPWpGaD
Flutamide—CYP1A1—lymph node—colon cancer	0.00126	0.00774	CbGeAlD
Flutamide—Discomfort—Irinotecan—colon cancer	0.00125	0.00523	CcSEcCtD
Flutamide—Oedema—Vincristine—colon cancer	0.00125	0.00521	CcSEcCtD
Flutamide—Jaundice—Capecitabine—colon cancer	0.00124	0.00519	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—MSH2—colon cancer	0.00123	0.00511	CbGpPWpGaD
Flutamide—Confusional state—Irinotecan—colon cancer	0.00123	0.00511	CcSEcCtD
Flutamide—AR—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.00122	0.00507	CbGpPWpGaD
Flutamide—Thrombocytopenia—Vincristine—colon cancer	0.00122	0.0051	CcSEcCtD
Flutamide—Haematuria—Capecitabine—colon cancer	0.00122	0.00507	CcSEcCtD
Flutamide—Oedema—Irinotecan—colon cancer	0.00122	0.00507	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—PPARG—colon cancer	0.00121	0.005	CbGpPWpGaD
Flutamide—CYP3A4—liver—colon cancer	0.00121	0.00741	CbGeAlD
Flutamide—AHR—Adipogenesis—CTNNB1—colon cancer	0.0012	0.00499	CbGpPWpGaD
Flutamide—Discomfort—Fluorouracil—colon cancer	0.0012	0.00501	CcSEcCtD
Flutamide—Thrombocytopenia—Irinotecan—colon cancer	0.00119	0.00497	CcSEcCtD
Flutamide—Anorexia—Vincristine—colon cancer	0.00119	0.00496	CcSEcCtD
Flutamide—AHR—Adipogenesis—CDKN1A—colon cancer	0.00118	0.00488	CbGpPWpGaD
Flutamide—Confusional state—Fluorouracil—colon cancer	0.00117	0.0049	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.00117	0.00483	CbGpPWpGaD
Flutamide—Oedema—Fluorouracil—colon cancer	0.00116	0.00486	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—SRC—colon cancer	0.00116	0.00481	CbGpPWpGaD
Flutamide—Anorexia—Irinotecan—colon cancer	0.00116	0.00483	CcSEcCtD
Flutamide—Hepatitis—Capecitabine—colon cancer	0.00114	0.00478	CcSEcCtD
Flutamide—Thrombocytopenia—Fluorouracil—colon cancer	0.00114	0.00476	CcSEcCtD
Flutamide—Insomnia—Vincristine—colon cancer	0.00113	0.00471	CcSEcCtD
Flutamide—Oedema peripheral—Capecitabine—colon cancer	0.00113	0.00471	CcSEcCtD
Flutamide—Anorexia—Fluorouracil—colon cancer	0.00111	0.00463	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00111	0.00463	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.00111	0.00459	CbGpPWpGaD
Flutamide—Insomnia—Irinotecan—colon cancer	0.0011	0.00459	CcSEcCtD
Flutamide—Decreased appetite—Vincristine—colon cancer	0.00108	0.00453	CcSEcCtD
Flutamide—Somnolence—Irinotecan—colon cancer	0.00108	0.00451	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.00108	0.00447	CbGpPWpGaD
Flutamide—Fatigue—Vincristine—colon cancer	0.00108	0.00449	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.00107	0.00443	CbGpPWpGaD
Flutamide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00107	0.00442	CbGpPWpGaD
Flutamide—Constipation—Vincristine—colon cancer	0.00107	0.00445	CcSEcCtD
Flutamide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.00106	0.00441	CbGpPWpGaD
Flutamide—Decreased appetite—Irinotecan—colon cancer	0.00106	0.00441	CcSEcCtD
Flutamide—Insomnia—Fluorouracil—colon cancer	0.00105	0.00439	CcSEcCtD
Flutamide—Fatigue—Irinotecan—colon cancer	0.00105	0.00437	CcSEcCtD
Flutamide—Constipation—Irinotecan—colon cancer	0.00104	0.00434	CcSEcCtD
Flutamide—CYP2C19—Metapathway biotransformation—CHST5—colon cancer	0.00104	0.0043	CbGpPWpGaD
Flutamide—Somnolence—Fluorouracil—colon cancer	0.00103	0.00432	CcSEcCtD
Flutamide—Decreased appetite—Fluorouracil—colon cancer	0.00101	0.00422	CcSEcCtD
Flutamide—Feeling abnormal—Irinotecan—colon cancer	0.001	0.00418	CcSEcCtD
Flutamide—Erythema—Capecitabine—colon cancer	0.000997	0.00416	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000993	0.00412	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000981	0.00406	CbGpPWpGaD
Flutamide—Erectile dysfunction—Methotrexate—colon cancer	0.000981	0.00409	CcSEcCtD
Flutamide—AHR—Adipogenesis—TGFB1—colon cancer	0.000973	0.00403	CbGpPWpGaD
Flutamide—Photosensitivity reaction—Methotrexate—colon cancer	0.000972	0.00406	CcSEcCtD
Flutamide—Feeling abnormal—Fluorouracil—colon cancer	0.000959	0.004	CcSEcCtD
Flutamide—Drowsiness—Methotrexate—colon cancer	0.000949	0.00396	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000941	0.0039	CbGpPWpGaD
Flutamide—Ill-defined disorder—Capecitabine—colon cancer	0.000925	0.00386	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000923	0.00382	CbGpPWpGaD
Flutamide—Anaemia—Capecitabine—colon cancer	0.000921	0.00384	CcSEcCtD
Flutamide—Haematuria—Methotrexate—colon cancer	0.000905	0.00378	CcSEcCtD
Flutamide—AR—FOXA1 transcription factor network—EP300—colon cancer	0.000902	0.00374	CbGpPWpGaD
Flutamide—Malaise—Capecitabine—colon cancer	0.000899	0.00375	CcSEcCtD
Flutamide—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000896	0.00371	CbGpPWpGaD
Flutamide—Asthenia—Vincristine—colon cancer	0.000895	0.00374	CcSEcCtD
Flutamide—Leukopenia—Capecitabine—colon cancer	0.000892	0.00372	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—colon cancer	0.000885	0.00367	CbGpPWpGaD
Flutamide—AR—Nongenotropic Androgen signaling—PIK3CA—colon cancer	0.000883	0.00366	CbGpPWpGaD
Flutamide—Asthenia—Irinotecan—colon cancer	0.000872	0.00364	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	0.000867	0.00359	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000865	0.00359	CbGpPWpGaD
Flutamide—Hypertension—Capecitabine—colon cancer	0.00086	0.00359	CcSEcCtD
Flutamide—AR—Notch-mediated HES/HEY network—EP300—colon cancer	0.000855	0.00354	CbGpPWpGaD
Flutamide—Diarrhoea—Vincristine—colon cancer	0.000854	0.00356	CcSEcCtD
Flutamide—Hepatitis—Methotrexate—colon cancer	0.000852	0.00356	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000847	0.00351	CbGpPWpGaD
Flutamide—Anxiety—Capecitabine—colon cancer	0.000845	0.00353	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000843	0.00352	CcSEcCtD
Flutamide—Discomfort—Capecitabine—colon cancer	0.000838	0.0035	CcSEcCtD
Flutamide—Diarrhoea—Irinotecan—colon cancer	0.000831	0.00347	CcSEcCtD
Flutamide—Dizziness—Vincristine—colon cancer	0.000825	0.00344	CcSEcCtD
Flutamide—Pruritus—Fluorouracil—colon cancer	0.000823	0.00344	CcSEcCtD
Flutamide—Confusional state—Capecitabine—colon cancer	0.00082	0.00342	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—HRAS—colon cancer	0.000817	0.00338	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—colon cancer	0.000815	0.00337	CbGpPWpGaD
Flutamide—Oedema—Capecitabine—colon cancer	0.000813	0.00339	CcSEcCtD
Flutamide—CYP1B1—Arachidonic acid metabolism—PTGS2—colon cancer	0.000811	0.00336	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—CHST5—colon cancer	0.000808	0.00335	CbGpPWpGaD
Flutamide—Dizziness—Irinotecan—colon cancer	0.000804	0.00335	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.0008	0.00331	CbGpPWpGaD
Flutamide—Diarrhoea—Fluorouracil—colon cancer	0.000796	0.00332	CcSEcCtD
Flutamide—Thrombocytopenia—Capecitabine—colon cancer	0.000796	0.00332	CcSEcCtD
Flutamide—Vomiting—Vincristine—colon cancer	0.000793	0.00331	CcSEcCtD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000792	0.00328	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—EP300—colon cancer	0.00079	0.00327	CbGpPWpGaD
Flutamide—Skin disorder—Capecitabine—colon cancer	0.00079	0.0033	CcSEcCtD
Flutamide—Rash—Vincristine—colon cancer	0.000787	0.00328	CcSEcCtD
Flutamide—Dermatitis—Vincristine—colon cancer	0.000786	0.00328	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000784	0.00325	CbGpPWpGaD
Flutamide—Headache—Vincristine—colon cancer	0.000782	0.00326	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—EP300—colon cancer	0.000777	0.00322	CbGpPWpGaD
Flutamide—Anorexia—Capecitabine—colon cancer	0.000775	0.00324	CcSEcCtD
Flutamide—Vomiting—Irinotecan—colon cancer	0.000773	0.00322	CcSEcCtD
Flutamide—Dizziness—Fluorouracil—colon cancer	0.00077	0.00321	CcSEcCtD
Flutamide—Rash—Irinotecan—colon cancer	0.000766	0.0032	CcSEcCtD
Flutamide—Dermatitis—Irinotecan—colon cancer	0.000766	0.00319	CcSEcCtD
Flutamide—Headache—Irinotecan—colon cancer	0.000761	0.00318	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000758	0.00314	CbGpPWpGaD
Flutamide—AR—Regulation of Androgen receptor activity—SRC—colon cancer	0.000755	0.00313	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—CCND1—colon cancer	0.000754	0.00313	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—colon cancer	0.000747	0.00309	CbGpPWpGaD
Flutamide—Erythema—Methotrexate—colon cancer	0.000742	0.0031	CcSEcCtD
Flutamide—Nausea—Vincristine—colon cancer	0.000741	0.00309	CcSEcCtD
Flutamide—Vomiting—Fluorouracil—colon cancer	0.00074	0.00309	CcSEcCtD
Flutamide—Insomnia—Capecitabine—colon cancer	0.000736	0.00307	CcSEcCtD
Flutamide—Rash—Fluorouracil—colon cancer	0.000734	0.00306	CcSEcCtD
Flutamide—Dermatitis—Fluorouracil—colon cancer	0.000733	0.00306	CcSEcCtD
Flutamide—Headache—Fluorouracil—colon cancer	0.000729	0.00304	CcSEcCtD
Flutamide—Nausea—Irinotecan—colon cancer	0.000722	0.00301	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—AKT1—colon cancer	0.000721	0.00299	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000721	0.00299	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000721	0.00299	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000711	0.00294	CbGpPWpGaD
Flutamide—Decreased appetite—Capecitabine—colon cancer	0.000707	0.00295	CcSEcCtD
Flutamide—Fatigue—Capecitabine—colon cancer	0.000701	0.00293	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000701	0.0029	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000701	0.0029	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000699	0.0029	CbGpPWpGaD
Flutamide—Constipation—Capecitabine—colon cancer	0.000696	0.0029	CcSEcCtD
Flutamide—Nausea—Fluorouracil—colon cancer	0.000691	0.00288	CcSEcCtD
Flutamide—Ill-defined disorder—Methotrexate—colon cancer	0.000688	0.00287	CcSEcCtD
Flutamide—Anaemia—Methotrexate—colon cancer	0.000686	0.00286	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000683	0.00283	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000675	0.00279	CbGpPWpGaD
Flutamide—Feeling abnormal—Capecitabine—colon cancer	0.00067	0.0028	CcSEcCtD
Flutamide—Malaise—Methotrexate—colon cancer	0.000669	0.00279	CcSEcCtD
Flutamide—Leukopenia—Methotrexate—colon cancer	0.000664	0.00277	CcSEcCtD
Flutamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000642	0.00266	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000628	0.0026	CbGpPWpGaD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000627	0.00262	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000627	0.0026	CbGpPWpGaD
Flutamide—Discomfort—Methotrexate—colon cancer	0.000624	0.0026	CcSEcCtD
Flutamide—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.000624	0.00258	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000615	0.00255	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000615	0.00255	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000612	0.00254	CbGpPWpGaD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000611	0.00253	CbGpPWpGaD
Flutamide—Confusional state—Methotrexate—colon cancer	0.00061	0.00255	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—colon cancer	0.000607	0.00252	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—colon cancer	0.000601	0.00249	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000601	0.00249	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.0006	0.00249	CbGpPWpGaD
Flutamide—Thrombocytopenia—Methotrexate—colon cancer	0.000593	0.00247	CcSEcCtD
Flutamide—CYP1B1—Metabolism—CA7—colon cancer	0.000589	0.00244	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000588	0.00244	CbGpPWpGaD
Flutamide—Skin disorder—Methotrexate—colon cancer	0.000588	0.00245	CcSEcCtD
Flutamide—Asthenia—Capecitabine—colon cancer	0.000584	0.00244	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	0.000582	0.00241	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000581	0.00241	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000579	0.0024	CbGpPWpGaD
Flutamide—Anorexia—Methotrexate—colon cancer	0.000577	0.00241	CcSEcCtD
Flutamide—Pruritus—Capecitabine—colon cancer	0.000575	0.0024	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—TP53—colon cancer	0.000565	0.00234	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—colon cancer	0.000559	0.00232	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—CCND1—colon cancer	0.000558	0.00231	CbGpPWpGaD
Flutamide—Diarrhoea—Capecitabine—colon cancer	0.000556	0.00232	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	0.000553	0.00229	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—CTNNB1—colon cancer	0.000552	0.00229	CbGpPWpGaD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000551	0.00228	CbGpPWpGaD
Flutamide—Insomnia—Methotrexate—colon cancer	0.000548	0.00229	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—CDKN1A—colon cancer	0.000539	0.00223	CbGpPWpGaD
Flutamide—Somnolence—Methotrexate—colon cancer	0.000538	0.00225	CcSEcCtD
Flutamide—Dizziness—Capecitabine—colon cancer	0.000538	0.00224	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	0.000534	0.00221	CbGpPWpGaD
Flutamide—Decreased appetite—Methotrexate—colon cancer	0.000526	0.0022	CcSEcCtD
Flutamide—Fatigue—Methotrexate—colon cancer	0.000522	0.00218	CcSEcCtD
Flutamide—Vomiting—Capecitabine—colon cancer	0.000517	0.00216	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—EP300—colon cancer	0.000513	0.00213	CbGpPWpGaD
Flutamide—Rash—Capecitabine—colon cancer	0.000513	0.00214	CcSEcCtD
Flutamide—Dermatitis—Capecitabine—colon cancer	0.000512	0.00214	CcSEcCtD
Flutamide—Headache—Capecitabine—colon cancer	0.00051	0.00213	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.0005	0.00207	CbGpPWpGaD
Flutamide—CYP1A1—Arachidonic acid metabolism—PTGS2—colon cancer	0.000499	0.00207	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—SRC—colon cancer	0.000499	0.00207	CbGpPWpGaD
Flutamide—Feeling abnormal—Methotrexate—colon cancer	0.000499	0.00208	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000493	0.00204	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.00049	0.00203	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—HNF4A—colon cancer	0.000487	0.00202	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—colon cancer	0.000487	0.00202	CbGpPWpGaD
Flutamide—Nausea—Capecitabine—colon cancer	0.000483	0.00202	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	0.000482	0.002	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000467	0.00193	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000444	0.00184	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000444	0.00184	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000441	0.00183	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—EGFR—colon cancer	0.000437	0.00181	CbGpPWpGaD
Flutamide—Asthenia—Methotrexate—colon cancer	0.000434	0.00181	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000432	0.00179	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000432	0.00179	CbGpPWpGaD
Flutamide—Pruritus—Methotrexate—colon cancer	0.000428	0.00179	CcSEcCtD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000425	0.00176	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000421	0.00174	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—AKT1—colon cancer	0.00042	0.00174	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000415	0.00172	CbGpPWpGaD
Flutamide—Diarrhoea—Methotrexate—colon cancer	0.000414	0.00173	CcSEcCtD
Flutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—colon cancer	0.000409	0.00169	CbGpPWpGaD
Flutamide—Dizziness—Methotrexate—colon cancer	0.0004	0.00167	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000387	0.0016	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000386	0.0016	CbGpPWpGaD
Flutamide—Vomiting—Methotrexate—colon cancer	0.000385	0.00161	CcSEcCtD
Flutamide—CYP3A5—Metabolism—CA7—colon cancer	0.000384	0.00159	CbGpPWpGaD
Flutamide—Rash—Methotrexate—colon cancer	0.000382	0.00159	CcSEcCtD
Flutamide—Dermatitis—Methotrexate—colon cancer	0.000381	0.00159	CcSEcCtD
Flutamide—Headache—Methotrexate—colon cancer	0.000379	0.00158	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000378	0.00157	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000378	0.00157	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000375	0.00155	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000366	0.00151	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000365	0.00151	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CA7—colon cancer	0.000363	0.0015	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000362	0.0015	CbGpPWpGaD
Flutamide—Nausea—Methotrexate—colon cancer	0.00036	0.0015	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000358	0.00148	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CHST5—colon cancer	0.000357	0.00148	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—ODC1—colon cancer	0.000357	0.00148	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000352	0.00146	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	0.00034	0.00141	CbGpPWpGaD
Flutamide—CYP1A1—PPARA activates gene expression—PPARG—colon cancer	0.000338	0.0014	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000336	0.00139	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000335	0.00139	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	0.000334	0.00139	CbGpPWpGaD
Flutamide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.000331	0.00137	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—EP300—colon cancer	0.000328	0.00136	CbGpPWpGaD
Flutamide—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	0.000318	0.00132	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000318	0.00132	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000311	0.00129	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.00031	0.00129	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—AKT1—colon cancer	0.00031	0.00128	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000304	0.00126	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000303	0.00125	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.0003	0.00124	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000298	0.00123	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CA7—colon cancer	0.000297	0.00123	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000293	0.00121	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000293	0.00121	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000287	0.00119	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000283	0.00117	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000283	0.00117	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000279	0.00115	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000275	0.00114	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000275	0.00114	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000271	0.00112	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000271	0.00112	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000268	0.00111	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000265	0.0011	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000264	0.00109	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000247	0.00102	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000246	0.00102	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000243	0.00101	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000242	0.001	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000241	0.001	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000241	0.001	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000241	0.000997	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000237	0.000984	CbGpPWpGaD
Flutamide—AR—Gene Expression—HNF4A—colon cancer	0.000235	0.000972	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CHST5—colon cancer	0.000233	0.000964	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—ODC1—colon cancer	0.000233	0.000964	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CA7—colon cancer	0.000231	0.000958	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000228	0.000944	CbGpPWpGaD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000228	0.000944	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000224	0.000929	CbGpPWpGaD
Flutamide—CYP1A1—PPARA activates gene expression—EP300—colon cancer	0.000221	0.000916	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CHST5—colon cancer	0.00022	0.000911	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—ODC1—colon cancer	0.00022	0.000911	CbGpPWpGaD
Flutamide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.000216	0.000896	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—PPARG—colon cancer	0.000212	0.000876	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000206	0.000854	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000203	0.000842	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000199	0.000826	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000194	0.000803	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—ODC1—colon cancer	0.00018	0.000745	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CHST5—colon cancer	0.00018	0.000745	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CA7—colon cancer	0.000179	0.00074	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000168	0.000698	CbGpPWpGaD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000149	0.000618	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000147	0.00061	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CHST5—colon cancer	0.00014	0.000581	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—ODC1—colon cancer	0.00014	0.000581	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—MYC—colon cancer	0.000121	0.0005	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000116	0.00048	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—ODC1—colon cancer	0.000108	0.000448	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CHST5—colon cancer	0.000108	0.000448	CbGpPWpGaD
Flutamide—AR—Gene Expression—PPARG—colon cancer	0.000102	0.000422	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.64e-05	0.000399	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—ABCB1—colon cancer	9.43e-05	0.000391	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—TYMS—colon cancer	9.26e-05	0.000384	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	9.07e-05	0.000376	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.42e-05	0.000308	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	7.14e-05	0.000296	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.13e-05	0.000295	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PPARG—colon cancer	6.56e-05	0.000272	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—ABCB1—colon cancer	6.15e-05	0.000255	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—TYMS—colon cancer	6.04e-05	0.00025	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.94e-05	0.000246	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.84e-05	0.000242	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—ABCB1—colon cancer	5.81e-05	0.000241	CbGpPWpGaD
Flutamide—AR—Gene Expression—MYC—colon cancer	5.81e-05	0.000241	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.79e-05	0.00024	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—TYMS—colon cancer	5.7e-05	0.000236	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PTGS2—colon cancer	5.16e-05	0.000214	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.86e-05	0.000201	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—ABCB1—colon cancer	4.75e-05	0.000197	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—TYMS—colon cancer	4.67e-05	0.000193	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.55e-05	0.000189	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.39e-05	0.000182	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—EP300—colon cancer	4.29e-05	0.000178	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PPARG—colon cancer	4.28e-05	0.000177	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PPARG—colon cancer	4.04e-05	0.000167	CbGpPWpGaD
Flutamide—AR—Gene Expression—AKT1—colon cancer	4.03e-05	0.000167	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.79e-05	0.000157	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—ABCB1—colon cancer	3.7e-05	0.000153	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—TYMS—colon cancer	3.64e-05	0.000151	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.59e-05	0.000149	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PTGS2—colon cancer	3.36e-05	0.000139	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PPARG—colon cancer	3.31e-05	0.000137	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PTGS2—colon cancer	3.18e-05	0.000132	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PIK3CA—colon cancer	3.18e-05	0.000132	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—ABCB1—colon cancer	2.86e-05	0.000118	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—TYMS—colon cancer	2.81e-05	0.000116	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.8e-05	0.000116	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—EP300—colon cancer	2.8e-05	0.000116	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—EP300—colon cancer	2.64e-05	0.00011	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PTGS2—colon cancer	2.6e-05	0.000108	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—AKT1—colon cancer	2.59e-05	0.000107	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PPARG—colon cancer	2.58e-05	0.000107	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—EP300—colon cancer	2.16e-05	8.96e-05	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PIK3CA—colon cancer	2.07e-05	8.58e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PTGS2—colon cancer	2.03e-05	8.4e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PPARG—colon cancer	1.99e-05	8.24e-05	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PIK3CA—colon cancer	1.96e-05	8.1e-05	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—AKT1—colon cancer	1.69e-05	7.01e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—EP300—colon cancer	1.69e-05	6.98e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PIK3CA—colon cancer	1.6e-05	6.63e-05	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—AKT1—colon cancer	1.6e-05	6.62e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PTGS2—colon cancer	1.56e-05	6.48e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—AKT1—colon cancer	1.31e-05	5.42e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—EP300—colon cancer	1.3e-05	5.39e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PIK3CA—colon cancer	1.25e-05	5.17e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—AKT1—colon cancer	1.02e-05	4.22e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PIK3CA—colon cancer	9.62e-06	3.99e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—AKT1—colon cancer	7.86e-06	3.26e-05	CbGpPWpGaD
